Question explored with the scientific record
How bad is a 9 Ha1c
An HbA1c of 9% means your average blood sugar over the last three months is roughly 212 mg/dL. That is not a number to ignore.
The evidence is clear that this level of chronic hyperglycemia is linked to real damage across multiple organ systems. The DCCT baseline data showed that people with type 1 diabetes and an HbA1c around 9% already had higher albumin excretion rates, a marker of early kidney injury [9]. A 2017 study of over 6,000 adults with diabetes and kidney disease found that an HbA1c of 9% or higher was independently associated with a roughly 60% increase in all-cause mortality compared to the 6-7% reference group [15]. The same study showed a U-shaped curve: both very low and very high HbA1c carried extra risk. In a breast cancer cohort, women with poorly controlled diabetes (HbA1c >9%) had an all-cause mortality hazard ratio of 3.65 and a breast-cancer-specific mortality hazard ratio of 8.37 compared to well-controlled women [16]. A pilot MRI study found that diabetics with incompressible arteries (a sign of calcification) had significantly impaired calf muscle blood flow during exercise, with the worst perfusion in the group with the highest HbA1c [13]. And in adolescents with type 1 diabetes, an HbA1c above 6.5% was present in 89% of those who already had microvascular complications like retinopathy, neuropathy, or nephropathy [3].
The mechanism is not mysterious. Chronic hyperglycemia drives protein oxidation, lipid peroxidation, and endothelial dysfunction [29, 2]. It reduces the efficiency of brain networks [32] and impairs lung function [27]. It damages the microcirculation everywhere: eyes, kidneys, nerves, heart, skeletal muscle. An HbA1c of 9% is not a laboratory curiosity. It is a measure of cumulative metabolic stress that has already begun to leave a trace.
My call: an HbA1c of 9% is a serious signal that requires a meaningful intervention, not a casual one. The evidence does not tell you which drug or diet is best, but it tells you that staying at 9% carries a documented and measurable cost. Confidence: high.
Sources examined 32
-
The midterm effects of diabetes mellitus on quadriceps and patellar tendons in patients with knee arthrosis: a comparative radiological study
Diabetes mellitus does not significantly alter midterm patellar and quadriceps tendon dimensions in knee osteoarthritis patients, as assessed by X-ray, ultrasound, and MRI, though quadriceps tendon buckling is more common in diabetics and MRI signal distribution differs by group.
DOI: 10.1016/j.jdiacomp.2006.07.003 -
Relationship between circulating vascular cell adhesion molecule-1 and microvascular complications in Type 2 diabetes mellitus
In Japanese patients with Type 2 diabetes mellitus, circulating soluble VCAM-1 levels rise with micovascular complications (retinopathy, nephropathy, neuropathy) and, in multivariate analysis, diabetic nephropathy is the sole independent predictor of VCAM-1 concentration, sugges…
DOI: 10.1002/(sici)1096-9136(199808)15:8<661::aid-dia645>3.0.co;2-g -
Complications of Diabetes Among Adolescents Attending A Diabetic Clinic in Kigali City, Rwanda : A Cross Sectionnal Study
Microvascular complications are relatively common among adolescents with type 1 diabetes in Kigali, Rwanda, and are strongly linked to place of residence and prior hypoglycemia or hospitalization, underscoring poor glycemic control as a key driver.
DOI: 10.55677/ijcsmr/v5i7-02/2025 -
Acute Hypoglycemia Decreases Myocardial Blood Flow Reserve in Patients With Type 1 Diabetes Mellitus and in Healthy Humans
In both healthy humans and patients with type 1 diabetes, acute insulin-induced hypoglycemia reduces myocardial blood flow reserve (MBFR) as measured by myocardial contrast echocardiography, whereas insulin during euglycemia increases MBFR in controls but not markedly in diabeti…
DOI: 10.1161/CIRCULATIONAHA.110.992297 -
The Longer-Term Benefits and Harms of Glucagon-Like Peptide-1 Receptor Agonists: a Systematic Review and Meta-Analysis
This systematic review and meta-analysis evaluates the longer-term benefits and harms of glucagon-like peptide-1 receptor agonists (GLP1RAs) in patients with type 2 diabetes, finding that GLP1RAs reduce cardiovascular risk factors, microvascular and macrovascular complications, …
DOI: 10.1007/s11606-021-07105-9 -
Diabetic angiopathy in children
A comprehensive pediatric review detailing the development, detection, risk factors, and prevention of diabetic angiopathy (retinopathy and nephropathy) in children and adolescents with type 1 diabetes, highlighting the central role of glycemic control, puberty-related risk modu…
DOI: 10.1002/(sici)1096-9136(199712)14:12<1012::aid-dia479>3.0.co;2-h -
The Relationship Between Pregnancy and Long‐term Maternal Complications in the EURODIAB IDDM Complications Study
Parity in women with Type 1 diabetes across 31 European centers is associated with lower long-term risks of macroalbuminuria and proliferative retinopathy, suggesting a potential protective effect of pregnancy or a selection bias, though causality cannot be inferred from a cross…
DOI: 10.1111/j.1464-5491.1995.tb00530.x -
Tissue factor pathway inhibitor (TFPI) release after heparin stimulation is increased in Type 1 diabetic patients with albuminuria
Albuminuric Type 1 diabetes patients show higher basal and post-heparin TFPI release, with albuminuria tightly linked to increased TFPI activity and suggesting endothelial glycosaminoglycan alterations as a marker of microvascular dysfunction.
DOI: 10.1046/j.1464-5491.2003.00786.x -
Baseline analysis of renal function in the Diabetes Control and Complications Trial
Baseline analysis of renal function in the Diabetes Control and Complications Trial shows that early nephropathy markers (AER) correlate with glycemic control (HbA1c) and, in those with minimal retinopathy, with blood pressure and retinopathy level, suggesting a shared metabolic…
DOI: 10.1038/ki.1993.96 -
Cutaneous Microvascular Dysfunction Is Associated With Human Leukocyte Antigen-DQ in Youths With Type 1 Diabetes
Among youths with type 1 diabetes, the HLA-DQ2/8 genotype is associated with reduced endothelium-dependent cutaneous microvascular responses and higher sICAM-1, suggesting a genetic contribution to microvascular dysfunction in juvenile diabetes.
DOI: 10.1203/PDR.0b013e318165bfd4 -
The results of open observational trial DIAMOND
Real-world gliclazide MR in type 2 diabetes with inadequate glycemic control yields substantial HbA1c and fasting glucose reductions, weight loss, and albuminuria improvement with a low rate of hypoglycemia over six months.
DOI: 10.14341/2072-0351-6232 -
Ocular surface disease in patients with diabetic peripheral neuropathy
A cross-sectional study of 34 participants assessing ocular surface disease in diabetes with varying diabetic peripheral neuropathy (DPN) severity, finding higher tear osmolarity and reduced corneal nerve fibre length with greater DPN severity, diminished Schirmer's test values,…
DOI: 10.1136/bjophthalmol-2015-307369 -
Pilot study of contrast-free MRI reveals significantly impaired calf skeletal muscle perfusion in diabetes with incompressible peripheral arteries
A pilot study using contrast-free MRI to quantify calf skeletal muscle perfusion and oxygen extraction during isometric exercise in three groups (non-diabetic controls, diabetics with ABI < 1.3, and diabetics with ABI ≥ 1.3), demonstrating significantly impaired calf microcircul…
DOI: 10.1177/1358863X21996465 -
18bp Fragment Insertion/Deletion Polymorphism of Vascular Endothelial Growth Factor (VEGF) Gene with Diabetes Mellitus Type 2 and Diabetic Retinopathy Patients of Quetta, Balochistan, Pakistan
VEGF promoter 18bp insertion/deletion polymorphism (I/D) is linked to retinopathy risk in type 2 diabetes, with the DD genotype and D allele enriched in DR patients versus DM without retinopathy and controls in a Quetta, Pakistan cohort.
DOI: 10.4172/2155-6156.1000789 -
Diabetes Control and the Risks of ESRD and Mortality in Patients With CKD
In a large EMR-based cohort of adults with diabetes and non-dialysis CKD, HbA1c levels <6% and ≥9% were independently associated with higher all-cause mortality, while HbA1c was not independently linked to ESRD; the ESRD risk appeared modified by baseline kidney function (eGFR).
DOI: 10.1053/j.ajkd.2016.11.018 -
Good glycaemic control is associated with a better prognosis in breast cancer patients with type 2 diabetes mellitus
This retrospective cohort study investigates the relationship between glycaemic control, as measured by HbA1C levels, and breast cancer prognosis in women with type 2 diabetes mellitus, finding that well-controlled diabetes is associated with better survival outcomes.
DOI: 10.1007/s10238-018-0497-2 -
Haemoglobin A1c variability is a strong, independent predictor of all‐cause mortality in patients with type 2 diabetes
This study investigates the relationship between HbA1c variability and all-cause mortality in patients with type 2 diabetes, finding that HbA1c variability is a strong independent predictor of mortality, more so than average HbA1c levels.
DOI: 10.1111/dom.13306 -
Semaglutide: Oral GLP-1 Receptor Analogue
Oral semaglutide is presented as a promising, patient-friendly GLP-1 receptor agonist for type 2 diabetes, with HbA1c reductions, weight loss, and favorable cardiovascular safety demonstrated across the PIONEER trial program.
DOI: 10.54136/erwej-0101-10008 -
Building clinical risk score systems for predicting the all‐cause and expanded cardiovascular‐specific mortality of patients with type 2 diabetes
Two predictive risk scores incorporating visit-to-visit glycemic and blood pressure variability accurately forecast all-cause and expanded cardiovascular mortality in type 2 diabetes, with good discrimination in a Taiwanese cohort.
DOI: 10.1111/dom.14240 -
Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease
Among high-risk adults with type 2 diabetes and established cardiovascular disease, tirzepatide is associated with a lower risk of a broad 6-component cardiorenal end point than dulaglutide, driven by reductions in all-cause mortality, myocardial infarction, coronary revasculari…
DOI: 10.1001/jamacardio.2026.0767 -
Liraglutide for the prevention of major adverse cardiovascular events in diabetic patients
A narrative review summarizing liraglutide's pharmacology, cardiovascular risk factor effects, and cardiovascular outcome trials, showing liraglutide reduces major adverse cardiovascular events and cardiovascular mortality in high-risk patients, with varying results among GLP-1 …
DOI: 10.1080/14779072.2019.1615444 -
<p>Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date</p>
This article reviews the development, pharmacology, and clinical evidence for oral semaglutide in type 2 diabetes, detailing its efficacy (glycemic control and weight loss), cardiovascular safety (non-inferiority with potential mortality benefits in PIONEER-6), safety profile (G…
DOI: 10.2147/DMSO.S229802 -
Cardiovascular safety of liraglutide for the treatment of type 2 diabetes
Cardiovascular safety of liraglutide in type 2 diabetes is discussed, with LEADER showing a reduction in major adverse cardiovascular events and mortality and meta-analyses suggesting no increased CV risk across trials.
DOI: 10.1080/14740338.2017.1313225 -
Testosterone levels and type 2 diabetes in men: current knowledge and clinical implications
This narrative review reports that low testosterone and SHBG are associated with type 2 diabetes and cardiometabolic risk in men and that testosterone therapy has inconsistent metabolic benefits and unresolved cardiovascular safety concerns.
DOI: 10.2147/dmso.s50777 -
Glycosylated haemoglobin is markedly elevated in new and known diabetes patients with hyperglycaemic ketoacidosis
A retrospective study of 83 diabetic ketoacidosis (DKA) admissions (2008-2009) shows markedly elevated HbA1c across known Type 1, known Type 2, and newly diagnosed diabetes at presentation, suggesting chronic hyperglycemia underlies most DKA events and HbA1c testing at presentat…
DOI: 10.4314/ahs.v14i3.5 -
Chronic Hyperglycemia and Subclinical Myocardial Injury
This study investigates the association between chronic hyperglycemia, as measured by glycated hemoglobin (HbA1c), and subclinical myocardial injury, indicated by elevated high-sensitivity cardiac troponin T (hs-cTnT), in a population free of clinically evident coronary heart di…
DOI: 10.1016/j.jacc.2011.10.875 -
FVC, FEV1 And FEV1/FVC% In Type-1 Diabetic Male And Their Relationships With HbA1c
Type-1 diabetic Bangladeshi men show reduced FVC and FEV1 compared with matched controls, with HbA1c negatively correlating with these lung function measures, implying poor glycemic control is linked to impaired pulmonary function.
DOI: 10.3329/jbsp.v7i1.11156 -
The influence of blood glucose on neutrophil function in individuals without diabetes
This study investigates the relationship between blood glucose levels and neutrophil function in a Japanese population without diabetes, revealing that chronic hyperglycemia increases basal reactive oxygen species production in postmenopausal women, potentially heightening their…
DOI: 10.1002/bio.2495 -
Protein oxidation parameters in type 2 diabetic patients with good and poor glycaemic control
This study investigates whether poor glycemic control in type 2 diabetes is linked to increased plasma markers of protein oxidation (PCO, T-SH, AOPP) and lipid peroxidation (LHP), comparing patients with good versus poor glycemic control, and finds higher PCO, AOPP, and LHP in p…
DOI: 10.1016/s1262-3636(07)70230-6 -
Role of Chronic and Acute Hyperglycemia in the Development of Diabetes Complications
This study investigates the roles of chronic and acute hyperglycemia in the development of diabetes complications, highlighting the importance of managing both fasting and postprandial glucose levels to mitigate vascular damage.
DOI: 10.1089/dia.2010.0146 -
Glycemic control and its impact on oxidative stress biomarkers in type 2 diabetic patients treated with metformin: a cross-sectional analysis
A cross-sectional analysis comparing glycemic control with metformin (HbA1c <7%) versus uncontrolled diabetes and normoglycemic controls in Nigerian patients to assess associations with oxidative stress biomarkers (MDA, GSH-Px, CAT, TAC); findings show no major difference betwee…
DOI: 10.15448/1980-6108.2019.2.33630 -
Hyperglycemia Reduces Efficiency of Brain Networks in Subjects with Type 2 Diabetes
This study investigates the impact of severe hyperglycemia on the efficiency of brain networks in middle-aged individuals with poorly controlled type 2 diabetes, revealing lower network efficiency and longer path lengths associated with higher HbA1c levels.
DOI: 10.1371/journal.pone.0157268